SBP GROUP (01177) surged more than 6% at the market open following the release of its interim results, with shares climbing 6.05% to HK$5.08 at the time of writing, and transaction volume reaching HK$15.73 million.

On August 19, SBP GROUP unveiled its 2026 interim financials, showcasing an exceptional growth trajectory. Revenue hit an all-time high of 19.44 billion yuan, marking a 10.6% year-on-year increase, while adjusted net profit attributable to shareholders from core operations grew steadily to 3.34 billion yuan, a substantial 92.3% surge compared to the prior year.

During the first half of 2026, the company's innovative business entered a phase of concentrated value realization, driven by the approval of new products such as Rovaxitinib, Pelaigannan, and Naldemedine, alongside the expansion of indications for key drugs including Anlotinib, Cumosiclib, and Zongaitinib.

Notably, SBP GROUP continued to secure endorsements from leading global pharmaceutical companies through its source-driven innovation efforts. To date, the group has completed four major out-licensing deals, with total transaction value surpassing $7 billion and upfront payments exceeding $1 billion. This underscores that the company's R&D capabilities and production quality controls have earned comprehensive recognition from top-tier multinational corporations, positioning its business development and global expansion strategy for sustained, regularized output.

Meanwhile, under its dual strategic pillars of AI and internationalization, SBP GROUP's pipeline depth across its four core therapeutic areas—oncology, liver disease/cardiometabolic, respiratory/autoimmune, and surgery/analgesia—is steadily converting into a dense pipeline of commercialization achievements.